Navigation Links
Monoclonal antibody reduces exacerbations in asthmatics

b reduced the number of moderate exacerbations in patients with asthma, as monitored by morning and evening use of an electronic spirometer incorporating a clinical diary," said Dr. Hansel. "Although infliximab therapy did not show significant efficacy for the primary endpoint of monitoring peak expiratory flow (PEF), it did produce a significant decrease in the diurnal (during the day) variation in the PEF rate."

(With PEF monitoring, patients take as deep as a breath as possible, then exhale as forcefully as possible into the mouthpiece of the PEF meter for three tests. As a gauge for pulmonary function, it is especially useful in patients older than age five who have persistent moderate to severe asthma.)

"None of the exacerbations we saw in our study warranted treatment with oral corticosteroids or hospitalization, so they cannot be considered to have been severe," said Dr. Hansel.

The researchers noted there were no adverse events associated with using the monoclonal antibody for treatment.

"Given that infliximab therapy was well-tolerated and appeared to reduce the incidence of asthma exacerbations, anti-TNFá therapy merits further study in larger clinical trials in patients with severe asthma," concluded Dr. Hansel.


'"/>

Source:American Thoracic Society


Page: 1 2

Related biology news :

1. Secrets to antibodys success against West Nile Virus surprise scientists
2. New antibody shows promise as cure for anthrax
3. Computer models aid understanding of antibody-dependent enhancement in spread of dengue fever
4. High resolution snapshots detail dynamics of a cocaine antibody
5. Buckyballs boost antibodys chemotherapy payload
6. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
7. A single sugar found responsible for an antibodys ability to treat inflammation
8. A key antibody, IgG, links cells capture and disposal of germs
9. Male circumcision reduces risk of HIV transmission from women to men
10. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
11. New miniaturised chip dramatically reduces time taken for DNA analysis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Monoclonal antibody reduces exacerbations asthmatics

(Date:5/21/2013)... Cancers of all types become most deadly when they ... has reached this stage, it becomes very difficult for ... can develop. Now, researchers at the University of Missouri ... target lymphoma tumor cells wherever they may be in ... in the MU College of Veterinary Medicine, says being ...
(Date:5/21/2013)... Chemical Society (ACS), the world,s largest scientific society, ... Meeting & Exposition, September 8-12, 2013, in Indianapolis, ... Convention Center and at area hotels. , With ... span science,s horizons from astronomy to zoology ... online journalists a rich assortment of spot news ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... has captured another image of Iceland,s Eyjafjallajkull volcano ash ... ash into the air and the ash clouds are ... Terra satellite flew over the volcano on April 16 ... Resolution Imaging Spectroradiometer, or MODIS instrument aboard Terra captured ...
... have found a way to determine which somatic cells -- ... a primordial, embryonic-like state are the most viable for therapeutic ... the Journal of Biological Chemistry, two collaborating teams ... a marker they found in induced-pluripotent stem cells, or iPS ...
... Vienna, Austria, Friday 16 April 2010: Results from ... CongressTM 2010 press conference will help inform clinical practice ... alcoholic hepatitis. The first study demonstrated the ... from severe alcoholic hepatitis (SAH) earlier than the recommended ...
Cached Biology News:Chinese scientists discover marker indicating the developmental potential of stem cells 2New insights into treatment options for patients suffering from severe alcoholic hepatitis 2
(Date:5/22/2013)... York, NY (PRWEB) May 22, 2013 Mold ... Cleaning Products said that there is a way to cut ... it included on its latest post the details of a ... too much money. , Mold could be prevented, My Cleaning ... measures, the company stated that a mold remediation must then ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Envera announced ... Fermentation Manager. Mr. McErlean has an extensive background ... leadership positions throughout his career. , Mike ... very pleased to have Mike join our team”. “Mike’s ... large scale fermentation and downstream processing equipment”, ...
(Date:5/22/2013)... 2013  Moderna Therapeutics, the pioneering company developing messenger ... the in vivo production of therapeutic proteins, ... will join Moderna in early July as its first ... proven leader in the design and implementation of information ... to translation, clinical operations and commercial preparedness. John has ...
(Date:5/21/2013)... NEW YORK , May 21, 2013  The Lindsley ... announced today that it is a Grand Challenges Explorations ... Melinda Gates Foundation .  Dr. Sara Lustigman ... an innovative global health and development research project, titled ... worms.  These worms are needed to screen drugs to ...
Breaking Biology Technology:How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2Envera Appoints Michael McErlean Fermentation Manager 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3
... Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... associated with abnormal auto-immune responses and inflammation, today ... Officer, will present at Citi,s 2011 Global Health ... March 1, 2011, at approximately 1:30 pm Eastern ...
... revenues totaled 153.5 million euro in 2010 (approximately 211.4 ... million euro, or approximately 169.9 million USD). This performance ... Yondelis® sales. Net sales in the Biopharmaceutical ... USD) in 2010 (51.1 million euro, or approximately 70.3 ...
... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a study ... Pathology demonstrated the ability of the ... of the highest risk HPV genotypes causing 70 percent of cervical ... study, which involved more than 47,000 women, validates the cobas ...
Cached Biology Technology:74 Percent EBITDA Improvement at Zeltia Group in 2010 2Pivotal Study Validates Roche's cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer 2Pivotal Study Validates Roche's cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer 3
... a high performance spectral scanning multimode ... With the advanced SkanIt Software it ... drug discovery assay development. Varioskan provides ... time-resolved fluorescence and photometric assays and ...
Strip Removal Tool 25/Box...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
... Protein Phosphatase ( l-PPase) ... phosphatase with activity towards ... tyrosine residues. It is ... of the ORF221 open ...
Biology Products: